{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:11:47Z","timestamp":1791922307937,"version":"4.3.4"},"reference-count":395,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000867","name":"RWJF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.vaccine.2015.10.080","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T06:36:00Z","timestamp":1454654160000},"page":"F1-F67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"S5","title":["The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper"],"prefix":"10.1016","volume":"33","author":[{"given":"Neal A.","family":"Halsey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawsar R.","family":"Talaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adena","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Mensah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Z.","family":"Dudley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Proveaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1542\/peds.2012-1255","article-title":"The burden of influenza in young children, 2004\u20132009","volume":"131","author":"Poehling","year":"2013","journal-title":"Pediatrics"},{"issue":"36","key":"10.1016\/j.vaccine.2015.10.080_bib0010","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2014.19.36.20900","article-title":"Did narcolepsy occur following administration of AS03-adjuvanted A(H1N1) pandemic vaccine in Ontario Canada? A review of post-marketing safety surveillance data","volume":"19","author":"Harris","year":"2014","journal-title":"Euro Surveill"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/spid.2002.125864","article-title":"The science of evaluation of adverse events associated with vaccination","volume":"13","author":"Halsey","year":"2002","journal-title":"Semin Pediatr Infect Dis"},{"issue":"44","key":"10.1016\/j.vaccine.2015.10.080_bib0020","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1016\/j.vaccine.2013.08.087","article-title":"Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use","volume":"31","author":"Tozzi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0025","series-title":"Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO AEFI causality assessment classification","author":"World Health Organization\/Global Vaccine Safety","year":"2013"},{"issue":"12","key":"10.1016\/j.vaccine.2015.10.080_bib0030","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1017\/S0950268811001531","article-title":"Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice","volume":"139","author":"Weldeselassie","year":"2011","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0035","series-title":"Adverse effects of vaccines: evidence and causality","author":"Institute of Medicine","year":"2012"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/COH.0b013e32834ddc96","article-title":"HIV vaccine development at the turn of the 21st century","volume":"7","author":"Girard","year":"2012","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1203\/PDR.0b013e3180686ce0","article-title":"Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple","volume":"62","author":"Polack","year":"2007","journal-title":"Pediatr Res"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib0050","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1542\/peds.2008-1002","article-title":"An algorithm for treatment of patients with hypersensitivity reactions after vaccines","volume":"122","author":"Wood","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0055","series-title":"Frequency of adverse drug reactions. Guidelines for preparing core clinical safety information on drugs report from CIOMS working group III, Geneva","author":"CIOMS","year":"1995"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4161\/hv.8.1.18859","article-title":"New technologies for influenza vaccines","volume":"8","author":"Dormitzer","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1586\/14760584.2014.852476","article-title":"Influenza vaccines: from whole-virus preparations to recombinant protein technology","volume":"13","author":"Huber","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0070","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1750-2659.2008.00055.x","article-title":"Yearly licensing studies from 1997 to 2007 of the inactivated whole-virus seasonal influenza vaccine fluval \u2013 a useful approach to pandemic vaccine development even in less well developed countries?","volume":"2","author":"Vajo","year":"2008","journal-title":"Influenza Other Respir Viruses"},{"issue":"41","key":"10.1016\/j.vaccine.2015.10.080_bib0075","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1016\/j.vaccine.2012.07.039","article-title":"A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory","volume":"30","author":"Loew-Baselli","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0080","doi-asserted-by":"crossref","first-page":"c2649","DOI":"10.1136\/bmj.c2649","article-title":"Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study","volume":"340","author":"Waddington","year":"2010","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1473-3099(10)70296-6","article-title":"Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial","volume":"11","author":"Nicholson","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.vaccine.2012.10.081","article-title":"Safety and immunogenicity of an adjuvanted whole virion, inactivated A (H1N1) 2009 influenza vaccine in young and elderly adults, and children","volume":"31","author":"Kulkarni","year":"2012","journal-title":"Vaccine"},{"issue":"9708","key":"10.1016\/j.vaccine.2015.10.080_bib0095","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)62003-1","article-title":"Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"375","author":"Liang","year":"2010","journal-title":"Lancet"},{"issue":"44","key":"10.1016\/j.vaccine.2015.10.080_bib0100","doi-asserted-by":"crossref","first-page":"7733","DOI":"10.1016\/j.vaccine.2011.07.128","article-title":"Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok\u00ae) against influenza in healthy adults: a randomized, placebo-controlled trial","volume":"29","author":"Treanor","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/infdis\/jit498","article-title":"Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population","volume":"209","author":"van der Velden","year":"2014","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2015.10.080_bib0110","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/CVI.00096-13","article-title":"An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A\/Chicken\/Astana\/6\/05) influenza vaccine is safe and immunogenic in a single dose in humans","volume":"20","author":"Sansyzbay","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2015.10.080_bib0115","doi-asserted-by":"crossref","first-page":"A34","DOI":"10.1016\/j.vaccine.2011.04.118","article-title":"Development of pandemic influenza vaccine production capacity in Viet Nam","volume":"29","author":"Hoa","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib0120","doi-asserted-by":"crossref","first-page":"e89829","DOI":"10.1371\/journal.pone.0089829","article-title":"Adverse drug reactions of spontaneous reports in shanghai pediatric population","volume":"9","author":"Li","year":"2014","journal-title":"PLOS ONE"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0125","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1086\/605506","article-title":"Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity","volume":"200","author":"Reisinger","year":"2009","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2015.10.080_bib0130","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1586\/erv.12.66","article-title":"Assessing the safety of influenza vaccination in specific populations: children and the elderly","volume":"11","author":"Rowhani-Rahbar","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0135","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.vaccine.2012.07.024","article-title":"Biologically plausible and evidence-based risk intervals in immunization safety research","volume":"31","author":"Rowhani-Rahbar","year":"2012","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2015.10.080_bib0140","doi-asserted-by":"crossref","first-page":"845","DOI":"10.4161\/hv.7.8.16271","article-title":"An evidence based protocol for the prevention of upper arm injury related to vaccine administration (UAIRVA)","volume":"7","author":"Cook","year":"2011","journal-title":"Hum Vaccin"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.080_bib0145","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.4161\/hv.25363","article-title":"A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age","volume":"9","author":"Pavia-Ruz","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"45","key":"10.1016\/j.vaccine.2015.10.080_bib0150","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1016\/j.vaccine.2009.02.004","article-title":"MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination","volume":"27","author":"Vesikari","year":"2009","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib0155","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/INF.0b013e31824bb179","article-title":"Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age","volume":"31","author":"Vesikari","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib0160","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1517\/14712591003724662","article-title":"MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk","volume":"10","author":"Durando","year":"2010","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0165","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/infdis\/jis427","article-title":"Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons","volume":"206","author":"Jackson","year":"2012","journal-title":"J Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2015.10.080_bib0170","first-page":"255","article-title":"Cellulitis reported to the Canadian adverse events following immunization surveillance system (1987\u20132012)","volume":"22","author":"Law","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib0175","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/pds.1390","article-title":"Evaluating adverse events after vaccination in the Medicare population","volume":"16","author":"Burwen","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib0180","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/00007611-199707000-00022","article-title":"Cellulitis and myositis caused by Agrobacterium radiobacter and Haemophilus parainfluenzae after influenza virus vaccination","volume":"90","author":"Owensby","year":"1997","journal-title":"South Med J"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib0185","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1525-1470.2009.00963.x","article-title":"The predilection of chickenpox exanthema to influenza vaccine injection site","volume":"26","author":"Ben-Shoshan","year":"2009","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib0190","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/all.12386","article-title":"Global classification and coding of hypersensitivity diseases \u2013 an EAACI \u2013 WAO survey, strategic paper and review","volume":"69","author":"Demoly","year":"2014","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib0195","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/all.12318","article-title":"Management of anaphylaxis: a systematic review","volume":"69","author":"Dhami","year":"2014","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1939-4551-7-9","article-title":"International consensus on (ICON) anaphylaxis","volume":"7","author":"Simons","year":"2014","journal-title":"World Allergy Organ J"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib0205","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm.2755","article-title":"IgE and mast cells in allergic disease","volume":"18","author":"Galli","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0210","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11882-012-0315-y","article-title":"Delayed anaphylaxis to red meat in patients with IgE specific for galactose alpha-1,3-galactose (alpha-gal)","volume":"13","author":"Commins","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0215","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/pai.12102","article-title":"Allergic reactions to vaccines","volume":"24","author":"Wood","year":"2013","journal-title":"Pediatr Allergy Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2015.10.080_bib0220","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1586\/14760584.2014.933079","article-title":"Administering influenza vaccine to egg-allergic persons","volume":"13","author":"Kelso","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0225","series-title":"Allergens table","author":"Institute for Vaccine Safety","year":"2013"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib0230","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1345\/aph.18301","article-title":"Risk of latex allergy from medication vial closures","volume":"33","author":"Smith","year":"1999","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0235","first-page":"27","article-title":"Large variations in the ovalbumin content in six European influenza vaccines","volume":"2006","author":"Mark","year":"2006","journal-title":"Pharmeur Sci Notes"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0240","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jaci.2011.02.003","article-title":"Ovalbumin content of 2010\u20132011 influenza vaccines","volume":"127","author":"McKinney","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0245","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaci.2012.04.003","article-title":"Adverse reactions to vaccines practice parameter 2012 update","volume":"130","author":"Kelso","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"32","key":"10.1016\/j.vaccine.2015.10.080_bib0250","first-page":"691","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) \u2013 United States, 2014\u201315 influenza season","volume":"63","author":"Grohskopf","year":"2014","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0255","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jaci.2010.10.005","article-title":"Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy","volume":"127","author":"Owens","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"28","key":"10.1016\/j.vaccine.2015.10.080_bib0260","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1016\/j.vaccine.2014.04.059","article-title":"Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada","volume":"32","author":"Rouleau","year":"2014","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.vaccine.2015.10.080_bib0265","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1016\/j.vaccine.2009.04.020","article-title":"Vaccination-associated anaphylaxis in adults: diagnostic testing ruling out IgE-mediated vaccine allergy","volume":"27","author":"Seitz","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0270","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jaci.2012.07.019","article-title":"Allergic symptoms after pandemic influenza vaccination rarely mediated by vaccine-specific IgE","volume":"130","author":"Rouleau","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib0275","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/MAJ.0b013e318273de7f","article-title":"Severe serum sickness after H1N1 influenza vaccination","volume":"345","author":"Bonds","year":"2013","journal-title":"Am J Med Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib0280","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1067\/mai.2002.126811","article-title":"Anaphylaxis: a review of causes and mechanisms","volume":"110","author":"Kemp","year":"2002","journal-title":"J Allergy Clin Immunol"},{"issue":"19\u201320","key":"10.1016\/j.vaccine.2015.10.080_bib0285","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1016\/S0264-410X(03)00094-X","article-title":"The clinical spectrum of the oculo-respiratory syndrome after influenza vaccination","volume":"21","author":"De Serres","year":"2003","journal-title":"Vaccine"},{"issue":"28","key":"10.1016\/j.vaccine.2015.10.080_bib0290","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1016\/j.vaccine.2005.01.154","article-title":"Oculo-respiratory syndrome after influenza vaccination: trends over four influenza seasons","volume":"23","author":"De Serres","year":"2005","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0295","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/jmv.10540","article-title":"Aggregate content influences the Th1\/Th2 immune response to influenza vaccine: evidence from a mouse model","volume":"72","author":"Babiuk","year":"2004","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0300","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/01.inf.0000148924.89558.d5","article-title":"Oculorespiratory syndrome after influenza immunization in children","volume":"24","author":"Skowronski","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0305","first-page":"1","article-title":"Supplementary Statement for the 2001\u20132002 season: influenza vaccination of persons who experienced oculo-respiratory syndrome following previous influenza vaccination","volume":"27","author":"National Advisory Committee on Immunization (NACI)","year":"2001","journal-title":"Can Commun Dis Rep"},{"issue":"51","key":"10.1016\/j.vaccine.2015.10.080_bib0310","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1016\/j.vaccine.2013.09.066","article-title":"Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS","volume":"31","author":"Halsey","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0315","first-page":"1","article-title":"Statement on influenza vaccination for the 2003\u20132004 season","volume":"29","author":"National Advisory Committee on Immunization (NACI)","year":"2003","journal-title":"Can Commun Dis Rep"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2015.10.080_bib0320","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1542\/peds.2012-0055G","article-title":"Standard 4: determining adequate sample sizes","volume":"129","author":"van der Tweel","year":"2012","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0325","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11882-010-0149-4","article-title":"Diagnosis of food allergy: epicutaneous skin tests, in vitro tests, and oral food challenge","volume":"11","author":"Lieberman","year":"2011","journal-title":"Curr Allergy Asthma Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib0330","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/INF.0b013e3181b84c34","article-title":"Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study","volume":"29","author":"Englund","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib0335","first-page":"259","article-title":"Annual report: surveillance of adverse events following immunisation in Australia, 2009","volume":"34","author":"Mahajan","year":"2010","journal-title":"Commun Dis Intell Q Rep"},{"issue":"31","key":"10.1016\/j.vaccine.2015.10.080_bib0340","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"R\u00fcggeberg","year":"2007","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib0345","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.arcmed.2011.10.007","article-title":"Events temporarily associated with anti-influenza A (H1N1) vaccination in Mexico","volume":"42","author":"Vidal","year":"2011","journal-title":"Arch Med Res"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib0350","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4161\/hv.7.5.14821","article-title":"Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations","volume":"7","author":"Banzhoff","year":"2011","journal-title":"Hum Vaccin"},{"issue":"37","key":"10.1016\/j.vaccine.2015.10.080_bib0355","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1016\/j.vaccine.2011.04.026","article-title":"Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective","volume":"29","author":"Tavares","year":"2011","journal-title":"Vaccine"},{"issue":"50","key":"10.1016\/j.vaccine.2015.10.080_bib0360","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1016\/j.vaccine.2013.10.033","article-title":"Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A\/H1N1 (H1N1pdm09) vaccine","volume":"31","author":"Rouleau","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib0365","doi-asserted-by":"crossref","first-page":"99","DOI":"10.7883\/yoken.65.99","article-title":"Adverse events following immunization (AEFI) with the novel influenza a (H1N1) 2009 vaccine: findings from the national registry of all vaccine recipients and AEFI and the passive surveillance system in South Korea","volume":"65","author":"Kim","year":"2012","journal-title":"Jpn J Infect Dis"},{"issue":"21","key":"10.1016\/j.vaccine.2015.10.080_bib0370","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.294.21.2720","article-title":"Adverse events reported following live, cold-adapted, intranasal influenza vaccine","volume":"294","author":"Izurieta","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib0375","first-page":"143","article-title":"Gianotti-Crosti syndrome in a child following intranasal influenza virus vaccination","volume":"19","author":"Domingues","year":"2009","journal-title":"Eur J Pediatr Dermatol"},{"issue":"19","key":"10.1016\/j.vaccine.2015.10.080_bib0380","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2169\/internalmedicine.49.4113","article-title":"Cutaneous vasculitis following influenza vaccination","volume":"49","author":"Liu","year":"2010","journal-title":"Intern Med"},{"issue":"11","key":"10.1016\/j.vaccine.2015.10.080_bib0385","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/infdis\/jir634","article-title":"Human rhinovirus species associated with hospitalizations for acute respiratory illness in young US children","volume":"204","author":"Iwane","year":"2011","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib0390","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00467-010-1722-8","article-title":"Henoch-Sch\u00f6nlein purpura following influenza vaccinations during the pandemic of influenza A (H1N1)","volume":"26","author":"Watanabe","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2015.10.080_bib0395","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.vaccine.2003.09.007","article-title":"Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation","volume":"22","author":"Marcy","year":"2004","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0400","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/oxfordjournals.aje.a112273","article-title":"Comparative trial of influenza vaccines, II. Adverse reactions in children and adults","volume":"104","author":"Barry","year":"1976","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0405","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3476(76)80722-6","article-title":"Clinical reactions and serologic response following inactivated monovalent influenza type B vaccine in young children and infants","volume":"88","author":"Wright","year":"1976","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0410","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2010-0665","article-title":"Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures","volume":"126","author":"Klein","year":"2010","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0415","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0022-3476(76)80721-4","article-title":"Reactions and serologic responses in young children and infants after administration of inactivated monovalent influenza A vaccine","volume":"88","author":"Marine","year":"1976","journal-title":"J Pediatr"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2015.10.080_bib0420","doi-asserted-by":"crossref","first-page":"S722","DOI":"10.1093\/infdis\/136.Supplement_3.S722","article-title":"Summary of clinical trials of influenza virus vaccines in adults","volume":"136","author":"Parkman","year":"1977","journal-title":"J Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2015.10.080_bib0425","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJM197704142961501","article-title":"Influenza A infections in young children. Primary natural infection and protective efficacy of live-vaccine-induced or naturally acquired immunity","volume":"296","author":"Wright","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0430","first-page":"309","article-title":"Inactivated influenza A\/New Jersey\/76 vaccines in children: results of a mult-center trial","volume":"39","author":"Wright","year":"1977","journal-title":"Dev Biol Stand"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0435","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/adc.83.6.488","article-title":"Safety and immunogenicity of a paediatric presentation of an influenza vaccine","volume":"83","author":"Gonzalez","year":"2000","journal-title":"Arch Dis Child"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib0440","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1542\/peds.69.4.404","article-title":"Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months","volume":"69","author":"Bernstein","year":"1982","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib0445","doi-asserted-by":"crossref","first-page":"316","DOI":"10.7326\/0003-4819-87-3-316","article-title":"Influenza vaccine: recommendations","volume":"87","author":"Public Health Service (PHS) Advisory Committee on Immunization Practices, Center for Disease Control, US Department of Health, Education, and Welfare; Atlanta, Georgia","year":"1977","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.080_bib0450","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.vaccine.2005.10.008","article-title":"Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip","volume":"24","author":"Delore","year":"2006","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0455","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1542\/peds.2005-2607","article-title":"Solicited adverse events after influenza immunization among infants, toddlers, and their household contacts","volume":"117","author":"Skowronski","year":"2006","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib0460","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1542\/peds.2004-2373","article-title":"A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children","volume":"115","author":"Englund","year":"2005","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.vaccine.2015.10.080_bib0465","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/INF.0b013e31825e6cd6","article-title":"Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity","volume":"31","author":"Langley","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"23","key":"10.1016\/j.vaccine.2015.10.080_bib0470","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.vaccine.2012.03.046","article-title":"Safety and immunogenicity of 2010\u20132011 H1N12009-containing trivalent inactivated influenza vaccine in children 12\u201359 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC\/CIHR Influenza Research Network (PCIRN) study","volume":"30","author":"Langley","year":"2012","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.080_bib0475","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/INF.0b013e3181e075be","article-title":"evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children","volume":"29","author":"Baxter","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib0480","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/infdis\/jit263","article-title":"Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children","volume":"208","author":"Langley","year":"2013","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2015.10.080_bib0485","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/infdis\/jit091","article-title":"A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3\u201317 years","volume":"207","author":"Domachowske","year":"2013","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0490","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/INF.0000000000000254","article-title":"Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age","volume":"33","author":"Greenberg","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"25","key":"10.1016\/j.vaccine.2015.10.080_bib0495","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1056\/NEJMoa0908535","article-title":"A novel influenza A (H1N1) vaccine in various age groups","volume":"361","author":"Zhu","year":"2009","journal-title":"N Engl J Med"},{"issue":"50","key":"10.1016\/j.vaccine.2015.10.080_bib0500","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1016\/j.vaccine.2008.08.046","article-title":"Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children","volume":"26","author":"Nolan","year":"2008","journal-title":"Vaccine"},{"issue":"36","key":"10.1016\/j.vaccine.2015.10.080_bib0505","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.1016\/j.vaccine.2010.06.065","article-title":"Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6\u201335 months","volume":"28","author":"Carmona","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0510","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/1471-2334-13-435","article-title":"Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials","volume":"13","author":"Launay","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.080_bib0515","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.vaccine.2013.11.031","article-title":"An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1\/2009 influenza vaccines in children 10\u201317 years of age","volume":"32","author":"Poder","year":"2014","journal-title":"Vaccine"},{"issue":"49","key":"10.1016\/j.vaccine.2015.10.080_bib0520","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2009.08.101","article-title":"MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database","volume":"27","author":"Pellegrini","year":"2009","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.vaccine.2015.10.080_bib0525","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1016\/j.vaccine.2010.08.075","article-title":"Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis","volume":"28","author":"Black","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib0530","doi-asserted-by":"crossref","first-page":"e1161","DOI":"10.1542\/peds.2010-1920","article-title":"Influenza A\/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months","volume":"127","author":"Esposito","year":"2011","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib0535","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/INF.0b013e31825687b0","article-title":"Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children","volume":"31","author":"Block","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"10.1016\/j.vaccine.2015.10.080_bib0540","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1097\/INF.0000000000000462","article-title":"Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived. A\/H1N1 pandemic influenza vaccine in children 6\u201335 months of age","volume":"33","author":"Knuf","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"46","key":"10.1016\/j.vaccine.2015.10.080_bib0545","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1016\/j.vaccine.2014.08.068","article-title":"Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children","volume":"32","author":"Nolan","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib0550","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/jamapediatrics.2013.4469","article-title":"Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine","volume":"168","author":"Stockwell","year":"2014","journal-title":"JAMA Pediatr"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0555","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1542\/peds.2008-0939","article-title":"Febrile seizures: clinical practice guideline for the long-term management of the child with simple febrile seizures","volume":"121","author":"American Academy of Pediatrics (AAP); Subcommittee on Febrile Seizures","year":"2008","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib0560","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1542\/peds.2010-3318","article-title":"Neurodiagnostic evaluation of the child with a simple febrile seizure","volume":"127","author":"American Academy of Pediatrics (AAP); Subcommittee on Febrile Seizures","year":"2011","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib0565","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1542\/peds.2005-0759","article-title":"Risk of intracranial pathologic conditions requiring emergency intervention after a first complex febrile seizure episode among children","volume":"117","author":"Teng","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0570","first-page":"2014","article-title":"Febrile seizures","author":"Mewasingh","year":"2014","journal-title":"Clin Evid (Online)"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib0575","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.braindev.2008.11.012","article-title":"Register-based studies on febrile seizures in Denmark","volume":"31","author":"Vestergaard","year":"2009","journal-title":"Brain Dev"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0580","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1515\/revneuro-2013-0053","article-title":"Genetic background of febrile seizures","volume":"25","author":"Saghazadeh","year":"2014","journal-title":"Rev Neurosci"},{"issue":"8","key":"10.1016\/j.vaccine.2015.10.080_bib0585","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1586\/14760584.2013.814781","article-title":"Vaccines and febrile seizures","volume":"12","author":"Principi","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib0590","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1542\/peds.2014-0690","article-title":"Etiologies for seizures around the time of vaccination","volume":"134","author":"Verbeek","year":"2014","journal-title":"Pediatrics"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2015.10.080_bib0595","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.vaccine.2003.09.008","article-title":"Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation","volume":"22","author":"Bonhoeffer","year":"2004","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib0600","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1542\/peds.2004-1519","article-title":"Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990\u20132003","volume":"115","author":"McMahon","year":"2005","journal-title":"Pediatrics"},{"issue":"32","key":"10.1016\/j.vaccine.2015.10.080_bib0605","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1016\/j.vaccine.2009.05.023","article-title":"Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6\u201323 months of age","volume":"27","author":"Rosenberg","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0610","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/INF.0b013e3181ff9795","article-title":"Adverse events following trivalent inactivated influenza vaccination in children: analysis of the vaccine adverse event reporting system","volume":"30","author":"Muhammad","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"10.1016\/j.vaccine.2015.10.080_bib0615","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archpedi.158.11.1031","article-title":"Safety of the trivalent inactivated influenza vaccine among children: a population-based study","volume":"158","author":"France","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"16","key":"10.1016\/j.vaccine.2015.10.080_bib0620","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1001\/jama.296.16.1990","article-title":"Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old","volume":"296","author":"Hambidge","year":"2006","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib0625","doi-asserted-by":"crossref","first-page":"e821","DOI":"10.1542\/peds.2005-2234","article-title":"The safety of trivalent influenza vaccine among healthy children 6 to 24 months of age","volume":"117","author":"Goodman","year":"2006","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.vaccine.2015.10.080_bib0630","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/archpediatrics.2011.112","article-title":"Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink","volume":"165","author":"Glanz","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib0635","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001912","article-title":"Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study","volume":"3","author":"Nazareth","year":"2013","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0640","doi-asserted-by":"crossref","first-page":"e000016","DOI":"10.1136\/bmjopen-2010-000016","article-title":"Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine","volume":"1","author":"Armstrong","year":"2011","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib0645","first-page":"263","article-title":"Annual report: surveillance of adverse events following immunisation in Australia, 2010","volume":"35","author":"Mahajan","year":"2011","journal-title":"Commun Dis Intell Q Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib0650","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/INF.0b013e31823d5303","article-title":"Influenza vaccine safety in children less than 5 years old: the 2010 and 2011 experience in Australia","volume":"31","author":"Wood","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0655","series-title":"Letter to general practitioners","author":"Salisbury","year":"2010"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0660","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2009.1911","article-title":"Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial","volume":"303","author":"Nolan","year":"2010","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib0665","first-page":"121","article-title":"Australian experience with non-adjuvant H1N1 vaccine (Panvax and Panvax Junior)","volume":"33","author":"Cook","year":"2010","journal-title":"Aust Prescr"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib0670","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/irv.12107","article-title":"Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents","volume":"7","author":"Lambert","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0675","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1750-2659.2009.00108.x","article-title":"Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children","volume":"3","author":"Nolan","year":"2009","journal-title":"Influenza Other Respir Viruses"},{"issue":"16","key":"10.1016\/j.vaccine.2015.10.080_bib0680","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1016\/j.vaccine.2011.02.012","article-title":"Fever following administration of two inactivated influenza vaccines-A survey of parents of New Zealand infants and children 5 years of age and under","volume":"29","author":"Petousis-Harris","year":"2011","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.vaccine.2015.10.080_bib0685","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1016\/j.vaccine.2013.09.005","article-title":"The risk of fever following one dose of trivalent inactivated influenza vaccine in children aged (greater-than or equal to)6 months to <36 months: a comparison of published and unpublished studies","volume":"31","author":"Kaczmarek","year":"2013","journal-title":"Vaccine"},{"issue":"51","key":"10.1016\/j.vaccine.2015.10.080_bib0690","doi-asserted-by":"crossref","first-page":"7400","DOI":"10.1016\/j.vaccine.2012.09.083","article-title":"Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza Vaccine","volume":"30","author":"Maraskovsky","year":"2012","journal-title":"Vaccine"},{"issue":"30","key":"10.1016\/j.vaccine.2015.10.080_bib0695","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1016\/j.vaccine.2014.03.035","article-title":"Role of viral RNA and lipid in the adverse events associated with the 2010 Southern Hemisphere trivalent influenza vaccine","volume":"32","author":"Rockman","year":"2014","journal-title":"Vaccine"},{"issue":"30","key":"10.1016\/j.vaccine.2015.10.080_bib0700","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1016\/j.vaccine.2014.03.032","article-title":"Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere trivalent influenza vaccine is associated with adverse events","volume":"32","author":"Rockman","year":"2014","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib0705","first-page":"53","article-title":"Global Advisory Committee on Vaccine Safety, 11\u201312 December 2013","volume":"89","author":"World Health Organization","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0710","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5694\/mja11.10941","article-title":"Adverse events associated with 2010 CSL and other inactivated influenza vaccines","volume":"195","author":"Kelly","year":"2011","journal-title":"Med J Aust"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib0715","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1056\/NEJMoa1008553","article-title":"Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China","volume":"364","author":"Liang","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0720","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.vaccine.2010.12.008","article-title":"Spontaneous reporting of adverse events following immunisation against pandemic influenza in Denmark November 2009\u2013March 2010","volume":"29","author":"Folkenberg","year":"2011","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2015.10.080_bib0725","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1016\/j.vaccine.2010.05.066","article-title":"Surveillance of adverse events following immunization against pandemic influenza in Slovenia in season 2009\/10","volume":"28","author":"Kraigher","year":"2010","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2015.10.080_bib0730","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2165\/11539270-000000000-00000","article-title":"Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands","volume":"33","author":"van Puijenbroek","year":"2010","journal-title":"Drug Saf"},{"issue":"51","key":"10.1016\/j.vaccine.2015.10.080_bib0735","doi-asserted-by":"crossref","first-page":"9467","DOI":"10.1016\/j.vaccine.2011.10.029","article-title":"Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database study","volume":"29","author":"Stowe","year":"2011","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2015.10.080_bib0740","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.vaccine.2011.12.042","article-title":"Febrile seizures after 2010\u20132011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system","volume":"30","author":"Leroy","year":"2012","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2015.10.080_bib0745","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.vaccine.2012.01.027","article-title":"Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010\u20132011","volume":"30","author":"Tse","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0750","first-page":"365","article-title":"Risk of febrile seizures in children following trivalent inactivated influenza vaccine in the vaccine safety datalink project, 2010\u20132011","volume":"21","author":"Tse","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0755","series-title":"Slide presentation at: meeting of the Advisory Committee on Immunization Practices (ACIP)","article-title":"Seizures following administration of multiple vaccines: a VSD study","author":"Duffy","year":"2014"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib0760","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/pds.3575","article-title":"Absence of associations between influenza vaccines and increased risks of seizures. Guillain-Barr\u00e9 syndrome, encephalitis, or anaphylaxis in the 2012\u20132013 season","volume":"23","author":"Kawai","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib0765","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1750-2659.2012.00364.x","article-title":"Increased reactions to pediatric influenza vaccination following concomitant pneumococcal vaccination","volume":"7","author":"Van Buynder","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0770","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.vaccine.2009.11.054","article-title":"Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children","volume":"28","author":"Lum","year":"2010","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.vaccine.2015.10.080_bib0775","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1016\/j.vaccine.2012.08.005","article-title":"A prospective observational safety study on MF59 (registered trademark) adjuvanted cell culture-derived vaccine. Celtura(registered trademark) during the A\/H1N1 (2009) influenza pandemic","volume":"30","author":"Reynales","year":"2012","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.vaccine.2015.10.080_bib0780","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1016\/j.vaccine.2014.09.018","article-title":"Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005\u2013June 2013","volume":"32","author":"Haber","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0785","series-title":"(Influenza vaccine live, intranasal), intranasal spray, 2014\u20132015 formula: package insert","author":"FluMist\u00ae Quadrivalent","year":"2014"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib0790","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJMoa065368","article-title":"Live attenuated versus inactivated influenza vaccine in infants and young children","volume":"356","author":"Belshe","year":"2007","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.vaccine.2015.10.080_bib0795","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1016\/j.vaccine.2011.04.113","article-title":"A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years","volume":"29","author":"Tennis","year":"2011","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.vaccine.2015.10.080_bib0800","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1016\/j.vaccine.2012.07.031","article-title":"A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009\u20132010 season","volume":"30","author":"Tennis","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0805","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1473-3099(13)70046-X","article-title":"AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial","volume":"13","author":"McElhaney","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0810","series-title":"Information sheet: observed rate of vaccine reactions \u2013 influenza vaccine","author":"World Health Organization\/Global Vaccine Safety","year":"2012"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.080_bib0815","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jama.1990.03450090075029","article-title":"Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial","volume":"264","author":"Margolis","year":"1990","journal-title":"JAMA"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2015.10.080_bib0820","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0002-9343(90)90123-U","article-title":"Frequency of adverse reactions after influenza vaccination","volume":"88","author":"Margolis","year":"1990","journal-title":"Am J Med"},{"issue":"14","key":"10.1016\/j.vaccine.2015.10.080_bib0825","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/archinte.1996.00440130090009","article-title":"Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial","volume":"156","author":"Nichol","year":"1996","journal-title":"Arch Intern Med"},{"issue":"44","key":"10.1016\/j.vaccine.2015.10.080_bib0830","doi-asserted-by":"crossref","first-page":"7656","DOI":"10.1016\/j.vaccine.2007.08.042","article-title":"Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects","volume":"25","author":"Couch","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0835","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/1471-2334-13-224","article-title":"Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults","volume":"13","author":"Beran","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"45","key":"10.1016\/j.vaccine.2015.10.080_bib0840","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1016\/j.vaccine.2010.09.021","article-title":"Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009\u2013January 31 2010","volume":"28","author":"Vellozzi","year":"2010","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2015.10.080_bib0845","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1016\/j.vaccine.2014.10.024","article-title":"Randomized trial to compare the safety and immunogenicity of CSL Limited's 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children","volume":"32","author":"Brady","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib0850","first-page":"216","article-title":"Immunogenicity, safety, and tolerability of two trivalent subunit inactivated influenza vaccines: a phase III, observer-blind, randomized, controlled multicenter study","volume":"25","author":"Tregnaghi","year":"2012","journal-title":"Viral Immunol"},{"issue":"21","key":"10.1016\/j.vaccine.2015.10.080_bib0855","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1001\/archinte.160.21.3243","article-title":"Clinical signs and symptoms predicting influenza infection","volume":"160","author":"Monto","year":"2000","journal-title":"Arch Intern Med"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.080_bib0860","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1097\/CCM.0b013e318180b039","article-title":"Influenza","volume":"36","author":"Beigel","year":"2008","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib0865","doi-asserted-by":"crossref","first-page":"e0118528","DOI":"10.1371\/journal.pone.0118528","article-title":"A cell-based systems biology assessment of human blood to monitor immune responses after influenza vaccination","volume":"10","author":"Hoek","year":"2015","journal-title":"PLOS ONE"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib0870","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.immuni.2012.12.008","article-title":"Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines","volume":"38","author":"Obermoser","year":"2013","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib0875","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.cyto.2012.08.004","article-title":"Differential serum cytokine responses to inactivated and live attenuated seasonal influenza vaccines","volume":"60","author":"Ramakrishnan","year":"2012","journal-title":"Cytokine"},{"issue":"48","key":"10.1016\/j.vaccine.2015.10.080_bib0880","doi-asserted-by":"crossref","first-page":"8982","DOI":"10.1016\/j.vaccine.2011.09.039","article-title":"Inflammatory responses to trivalent influenza virus vaccine among pregnant women","volume":"29","author":"Christian","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0885","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/aji.12117","article-title":"Serum proinflammatory cytokine responses to influenza virus vaccine among women during pregnancy versus non-pregnancy","volume":"70","author":"Christian","year":"2013","journal-title":"Am J Reprod Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2015.10.080_bib0890","first-page":"1566","article-title":"Proposal for the development of classification criteria for idiopathic arthritides of childhood","volume":"22","author":"Fink","year":"1995","journal-title":"J Rheumatol"},{"issue":"9563","key":"10.1016\/j.vaccine.2015.10.080_bib0895","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib0900","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11926-010-0087-0","article-title":"The genetics of juvenile idiopathic arthritis: what is new in 2010?","volume":"12","author":"Angeles-Han","year":"2010","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib0905","doi-asserted-by":"crossref","first-page":"A319","DOI":"10.1016\/j.autrev.2009.11.018","article-title":"Environmental factors and the geoepidemiology of juvenile idiopathic arthritis","volume":"9","author":"Berkun","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib0910","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00296-009-1253-4","article-title":"Do infections trigger juvenile idiopathic arthritis?","volume":"31","author":"Aslan","year":"2011","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.080_bib0915","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1128\/CVI.00309-12","article-title":"Relapse of systemic juvenile idiopathic arthritis after influenza vaccination in a patient receiving tocilizumab","volume":"19","author":"Shimizu","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib0920","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/s10165-005-0399-5","article-title":"Reactive arthritis after influenza vaccination: report of a case","volume":"15","author":"Asakawa","year":"2005","journal-title":"Mod Rheumatol"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib0925","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3109\/s10165-011-0418-7","article-title":"Onset of adult-onset Still's disease following influenza vaccination","volume":"21","author":"Yoshioka","year":"2011","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib0930","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1128\/CVI.00081-13","article-title":"Septic shock after seasonal influenza vaccination in an HIV-infected patient during treatment with etanercept for rheumatoid arthritis: a case report","volume":"20","author":"De Nardo","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib0935","first-page":"1203","article-title":"Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity","volume":"21","author":"Chalmers","year":"1994","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib0940","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/rheumatology\/36.3.366","article-title":"Patients who develop inflammatory polyarthritis (IP) after immunization are clinically indistinguishable from other patients with IP","volume":"36","author":"Harrison","year":"1997","journal-title":"Br J Rheumatol"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib0945","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard.2007.077461","article-title":"Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response","volume":"67","author":"Oren","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib0950","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3899\/jrheum.110721","article-title":"Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease","volume":"39","author":"Aikawa","year":"2012","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib0955","first-page":"436","article-title":"Safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis","volume":"30","author":"Toplak","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0960","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/art.30325","article-title":"Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study","volume":"63","author":"Gabay","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"10 Suppl","key":"10.1016\/j.vaccine.2015.10.080_bib0965","first-page":"1","article-title":"The cellular response to vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases","volume":"63","author":"Elkayam","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0970","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/ard.2011.150250","article-title":"Immunogenicity and safety of the 2009 non-adjuvanted influenza A\/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases","volume":"70","author":"Saad","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib0975","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3109\/s10165-012-0595-z","article-title":"Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab","volume":"22","author":"Shinoki","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"38","key":"10.1016\/j.vaccine.2015.10.080_bib0980","doi-asserted-by":"crossref","first-page":"6592","DOI":"10.1016\/j.vaccine.2011.06.112","article-title":"Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15\u201359 years of age","volume":"29","author":"Ray","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.080_bib0985","doi-asserted-by":"crossref","first-page":"d5956","DOI":"10.1136\/bmj.d5956","article-title":"Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden","volume":"343","author":"Bardage","year":"2011","journal-title":"BMJ"},{"issue":"19","key":"10.1016\/j.vaccine.2015.10.080_bib0990","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/j.vaccine.2012.02.039","article-title":"A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age","volume":"30","author":"Baxter","year":"2012","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.080_bib0995","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1136\/ard.2010.129908","article-title":"Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study","volume":"69","author":"Bengtsson","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib1000","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.vaccine.2006.08.034","article-title":"Vaccination-related shoulder dysfunction","volume":"25","author":"Bodor","year":"2007","journal-title":"Vaccine"},{"issue":"51","key":"10.1016\/j.vaccine.2015.10.080_bib1005","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1016\/j.vaccine.2010.10.005","article-title":"Shoulder injury related to vaccine administration (SIRVA)","volume":"28","author":"Atanasoff","year":"2010","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.080_bib1010","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00256-014-1875-9","article-title":"Magnetic resonance imaging of abnormal shoulder pain following influenza vaccination","volume":"43","author":"Okur","year":"2014","journal-title":"Skelet Radiol"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib1015","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3122\/jabfm.2012.06.110334","article-title":"A \u201cneedling\u201d problem: shoulder injury related to vaccine administration","volume":"25","author":"Barnes","year":"2012","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1020","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-007673","article-title":"Acute brachial neuritis following influenza vaccination","author":"Shaikh","year":"2012","journal-title":"BMJ Case Rep"},{"issue":"40","key":"10.1016\/j.vaccine.2015.10.080_bib1025","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1016\/j.vaccine.2011.07.052","article-title":"Atraumatic osteonecrosis of the humeral head after influenza A-(H1N1) v-2009 vaccination","volume":"29","author":"Kuether","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib1030","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1331\/JAPhA.2013.13503","article-title":"Vaccine administration: preventing serious shoulder injuries","volume":"53","author":"Foster","year":"2013","journal-title":"J Am Pharm Assoc"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib1035","doi-asserted-by":"crossref","first-page":"605","DOI":"10.4161\/hv.27232","article-title":"Subdeltoid\/subacromial bursitis associated with influenza vaccination","volume":"10","author":"Cook","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib1040","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jocn.2008.08.033","article-title":"Guillain-Barr\u00e9 syndrome: an update","volume":"16","author":"Vucic","year":"2009","journal-title":"J Clin Neurosci"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib1045","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1085-9489.2005.0010202.x","article-title":"The immunobiology of Guillain-Barr\u00e9 syndromes","volume":"10","author":"Willison","year":"2005","journal-title":"J Peripher Nerv Syst"},{"issue":"8","key":"10.1016\/j.vaccine.2015.10.080_bib1050","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/cid\/ciu005","article-title":"Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence","volume":"58","author":"Vellozzi","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib1055","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1371\/journal.pone.0000344","article-title":"Guillain-Barr\u00e9 syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database","volume":"2","author":"Tam","year":"2007","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib1060","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/aje\/kwn310","article-title":"Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database","volume":"169","author":"Stowe","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"21","key":"10.1016\/j.vaccine.2015.10.080_bib1065","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJM199511233332102","article-title":"Campylobacter jejuni infection and Guillain-Barr\u00e9 syndrome","volume":"333","author":"Rees","year":"1995","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib1070","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/01616412.1998.11740573","article-title":"Anti-GQ1b IgG antibody activities related to the severity of Miller Fisher syndrome","volume":"20","author":"Mizoguchi","year":"1998","journal-title":"Neurol Res"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib1075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/00002018-200225030-00001","article-title":"Monitoring the safety of vaccines: assessing the risks","volume":"25","author":"Ellenberg","year":"2002","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib1080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"issue":"9876","key":"10.1016\/j.vaccine.2015.10.080_bib1085","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(12)62189-8","article-title":"Association between Guillain-Barr\u00e9 syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis","volume":"381","author":"Salmon","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.080_bib1090","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/014107687907200908","article-title":"Guillain-Barr\u00e9 syndrome: the swine influenza virus vaccine incident in the United States of America, 1976\u201377: preliminary communication","volume":"72","author":"Langmuir","year":"1979","journal-title":"J R Soc Med"},{"issue":"32","key":"10.1016\/j.vaccine.2015.10.080_bib1095","first-page":"613","article-title":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) \u2013 United States, 2012\u201313 influenza season","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib1100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archneur.1982.00510130023004","article-title":"Guillain-Barr\u00e9 syndrome in the US Army","volume":"39","author":"Johnson","year":"1982","journal-title":"Arch Neurol"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1105","series-title":"Immunization safety review: influenza vaccines and neurological complications","author":"Institute of Medicine","year":"2003"},{"issue":"25","key":"10.1016\/j.vaccine.2015.10.080_bib1110","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199812173392501","article-title":"The Guillain-Barr\u00e9 syndrome and the 1992\u20131993 and 1993\u20131994 influenza vaccines","volume":"339","author":"Lasky","year":"1998","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.vaccine.2015.10.080_bib1115","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/archinte.166.20.2217","article-title":"Guillain-Barr\u00e9 syndrome after influenza vaccination in adults: a population-based study","volume":"166","author":"Juurlink","year":"2006","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib1120","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1086\/589624","article-title":"Anti-ganglioside antibody induction by swine (A\/NJ\/1976\/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barr\u00e9 syndrome","volume":"198","author":"Nachamkin","year":"2008","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib1125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1750-2659.2011.00294.x","article-title":"No evidence of a link between influenza vaccines and Guillain-Barre syndrome-associated antiganglioside antibodies","volume":"6","author":"Wang","year":"2012","journal-title":"Influenza Other Respir Viruses"},{"issue":"16","key":"10.1016\/j.vaccine.2015.10.080_bib1130","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/j.vaccine.2012.02.009","article-title":"Anti-ganglioside antibodies were not detected in human subjects infected with or vaccinated against 2009 pandemic influenza A (H1N1) virus","volume":"30","author":"Lei","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib1135","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib1140","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11908-011-0194-8","article-title":"Guillain-barr\u00e9 syndrome following influenza vaccination: causal or coincidental?","volume":"13","author":"Sejvar","year":"2011","journal-title":"Curr Infect Dis Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib1145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jama.1982.03320290041029","article-title":"Absence of P2 protein in swine flu vaccines","volume":"247","author":"Brostoff","year":"1982","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib1150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-5728(84)90037-7","article-title":"Experimental neuritis induced by a mixture of neural antigens and influenza vaccines. A possible model for Guillain-Barr\u00e9 syndrome","volume":"6","author":"Hjorth","year":"1984","journal-title":"J Neuroimmunol"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib1155","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archfami.9.7.617","article-title":"Does influenza vaccination exacerbate asthma? Analysis of a large cohort of children with asthma. Vaccine Safety Datalink Team","volume":"9","author":"Kramarz","year":"2000","journal-title":"Arch Fam Med"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.080_bib1160","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2105\/AJPH.2011.300510","article-title":"Surveillance for Guillain-Barr\u00e9 syndrome after influenza vaccination among the Medicare population, 2009\u20132010","volume":"102","author":"Burwen","year":"2012","journal-title":"Am J Public Health"},{"issue":"11","key":"10.1016\/j.vaccine.2015.10.080_bib1165","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/aje\/kws195","article-title":"Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009\u20132010","volume":"175","author":"Greene","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib1170","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/aje\/kwt051","article-title":"Chart-confirmed guillain-barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009\u20132010","volume":"178","author":"Polakowski","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib1175","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/pds.3220","article-title":"The risk of Guillain-Barr\u00e9 syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009\u20132010 seasonal influenza vaccines: results from self-controlled analyses","volume":"21","author":"Tokars","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.080_bib1180","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/sim.2302","article-title":"Tutorial in biostatistics: the self-controlled case series method","volume":"25","author":"Whitaker","year":"2006","journal-title":"Stat Med"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.080_bib1185","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/infdis\/jir561","article-title":"Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer","volume":"204","author":"Carr","year":"2011","journal-title":"J Infect Dis"},{"issue":"21","key":"10.1016\/j.vaccine.2015.10.080_bib1190","first-page":"657","article-title":"Preliminary results: surveillance for Guillain-Barr\u00e9 syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine \u2013 United States, 2009\u20132010","volume":"59","author":"CDC","year":"2010","journal-title":"Morb Mortal Wkly Rep"},{"issue":"40","key":"10.1016\/j.vaccine.2015.10.080_bib1195","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1016\/j.vaccine.2013.06.032","article-title":"International collaboration to assess the risk of Guillain Barr\u00e9 syndrome following influenza A (H1N1) 2009 monovalent vaccines","volume":"31","author":"Dodd","year":"2013","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2015.10.080_bib1200","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/pds.3638","article-title":"Risk of Guillain-Barr\u00e9 syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany","volume":"23","author":"Prestel","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib1205","doi-asserted-by":"crossref","first-page":"e58827","DOI":"10.1371\/journal.pone.0058827","article-title":"Safety of pandemic (H1N1) 2009 monovalent vaccines in taiwan: a self-controlled case series study","volume":"8","author":"Huang","year":"2013","journal-title":"PLOS ONE"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib1210","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10654-013-9797-8","article-title":"Risk of Guillain-Barr\u00e9 syndrome after 2010\u20132011 influenza vaccination","volume":"28","author":"Galeotti","year":"2013","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib1215","doi-asserted-by":"crossref","first-page":"e67185","DOI":"10.1371\/journal.pone.0067185","article-title":"Guillain-Barr\u00e9 syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case-centered analysis in the Vaccine Safety Datalink, 2009\u20132011","volume":"8","author":"Greene","year":"2013","journal-title":"PLOS ONE"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.080_bib1220","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1473-3099(13)70104-X","article-title":"Risk of Guillain-Barr\u00e9 syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study","volume":"13","author":"Kwong","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib1225","first-page":"69","article-title":"Neurological complications of immunization","volume":"2","author":"Reik","year":"1997","journal-title":"Neurol Infect Epidemiol"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib1230","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.spen.2012.02.004","article-title":"Neurologic complications of influenza","volume":"19","author":"Ekstrand","year":"2012","journal-title":"Semin Pediatr Neurol"},{"issue":"31","key":"10.1016\/j.vaccine.2015.10.080_bib1235","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1016\/j.vaccine.2007.04.060","article-title":"Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"25","author":"Sejvar","year":"2007","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.080_bib1240","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1586\/ern.09.90","article-title":"Acute disseminated encephalomyelitis: postinfectious, postimmunization and variant forms","volume":"9","author":"Behan","year":"2009","journal-title":"Expert Rev Neurother"},{"issue":"12","key":"10.1016\/j.vaccine.2015.10.080_bib1245","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.jocn.2008.05.002","article-title":"Post-vaccination encephalomyelitis: literature review and illustrative case","volume":"15","author":"Huynh","year":"2008","journal-title":"J Clin Neurosci"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.10.080_bib1250","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1007\/s10072-008-0966-6","article-title":"Acute disseminated encephalomyelitis","volume":"29","author":"Marchioni","year":"2008","journal-title":"Neurol Sci"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib1255","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s11910-005-0031-2","article-title":"Post-infectious encephalomyelitis","volume":"5","author":"Mihai","year":"2005","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2015.10.080_bib1260","first-page":"504","article-title":"Acute disseminated encephalomyelitis after H1N1 infection","volume":"17","author":"Ekmekc Di","year":"2010","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib1265","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJM198702123160703","article-title":"Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination","volume":"316","author":"Hemachudha","year":"1987","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.vaccine.2015.10.080_bib1270","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJM196911272812205","article-title":"Routine childhood vaccination against smallpox reconsidered","volume":"281","author":"Lane","year":"1969","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.vaccine.2015.10.080_bib1275","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2169\/internalmedicine.51.7132","article-title":"Simultaneous development of acute disseminated encephalomyelitis and Guillain-Barr\u00e9 syndrome associated with H1N1 09 influenza vaccination","volume":"51","author":"Hoshino","year":"2012","journal-title":"Intern Med"},{"issue":"Suppl. 14","key":"10.1016\/j.vaccine.2015.10.080_bib1280","first-page":"S122","article-title":"Variability in infectious disease testing for patients with acute disseminated encephalomyelitis","volume":"68","author":"Hopkins","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1285","first-page":"Doc32","article-title":"Acute disseminated encephalomyelitis as the first presentation of CNS tuberculosis: report of a case with brief review","volume":"8","author":"Masoodi","year":"2010","journal-title":"German Med Sci"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib1290","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/joim.12150","article-title":"Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up","volume":"275","author":"Persson","year":"2014","journal-title":"J Intern Med"},{"issue":"49","key":"10.1016\/j.vaccine.2015.10.080_bib1295","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.1016\/j.vaccine.2012.09.032","article-title":"Autoimmune disorders after immunisation with Influenza A\/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review","volume":"30","author":"Isai","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib1300","first-page":"180","article-title":"IMPACT network active surveillance for adverse events following adjuvanted pandemic influenza vaccine in Canadian children","volume":"21","author":"Sauve","year":"2010","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1305","doi-asserted-by":"crossref","first-page":"368","DOI":"10.12659\/AJCR.891416","article-title":"Influenza vaccine-induced CNS demyelination in a 50-year-old male","volume":"15","author":"Sacheli","year":"2014","journal-title":"Am J Case Rep"},{"issue":"40","key":"10.1016\/j.vaccine.2015.10.080_bib1310","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1016\/j.vaccine.2011.07.044","article-title":"Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004\u20132009","volume":"29","author":"Williams","year":"2011","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.vaccine.2015.10.080_bib1315","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.1016\/j.vaccine.2011.08.093","article-title":"Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination","volume":"29","author":"Williams","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1320","first-page":"673947","article-title":"Pediatric multiple sclerosis: current concepts and consensus definitions","volume":"2013","author":"Pena","year":"2013","journal-title":"Autoimmune Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib1325","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/gene.2011.42","article-title":"Epstein-Barr virus and multiple sclerosis: interaction with HLA","author":"Sundqvist","year":"2012","journal-title":"Genes Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib1330","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archneur.60.4.504","article-title":"Vaccinations and risk of central nervous system demyelinating diseases in adults","volume":"60","author":"DeStefano","year":"2003","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib1335","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1212\/01.WNL.0000138433.61870.82","article-title":"Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study","volume":"63","author":"Hern\u00e1n","year":"2004","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib1340","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000201564","article-title":"Association of infectious mononucleosis with multiple sclerosis. A population-based study","volume":"32","author":"Ramagopalan","year":"2009","journal-title":"Neuroepidemiology"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib1345","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s10072-003-0147-6","article-title":"Risk factors of multiple sclerosis: a case\u2013control study","volume":"24","author":"Zorzon","year":"2003","journal-title":"Neurol Sci"},{"issue":"11","key":"10.1016\/j.vaccine.2015.10.080_bib1350","doi-asserted-by":"crossref","first-page":"e50337","DOI":"10.1371\/journal.pone.0050337","article-title":"The impact of influenza vaccinations on the adverse effects and hospitalization rate in the elderly: a national based study in an Asian country","volume":"7","author":"Ho","year":"2012","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib1355","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00415-011-5984-2","article-title":"Immunizations and risk of multiple sclerosis: systematic review and meta-analysis","volume":"258","author":"Farez","year":"2011","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib1360","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1212\/WNL.48.2.312","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis","volume":"48","author":"Miller","year":"1997","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib1365","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM200102013440501","article-title":"Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group","volume":"344","author":"Confavreux","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib1370","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/135245859700300405","article-title":"Influenza virus vaccination of patients with multiple sclerosis","volume":"3","author":"Mokhtarian","year":"1997","journal-title":"Mult Scler"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2015.10.080_bib1375","doi-asserted-by":"crossref","first-page":"S546","DOI":"10.1093\/infdis\/136.Supplement_3.S546","article-title":"Swine influenza virus vaccination in patients with multiple sclerosis","volume":"136","author":"Myers","year":"1977","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib1380","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/archneur.1978.00500280060012","article-title":"Swine influenza vaccination in patients with multiple sclerosis","volume":"35","author":"Bamford","year":"1978","journal-title":"Arch Neurol"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1385","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jns.2011.10.013","article-title":"Seasonal and H1N1 v influenza vaccines in MS: safety and compliance","volume":"314","author":"Auriel","year":"2012","journal-title":"J Neuro Sci"},{"issue":"8","key":"10.1016\/j.vaccine.2015.10.080_bib1390","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00415-011-5944-x","article-title":"Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination","volume":"258","author":"McNicholas","year":"2011","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib1395","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S1474-4422(14)70075-4","article-title":"Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination","volume":"13","author":"Partinen","year":"2014","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib1400","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.vaccine.2012.12.014","article-title":"Narcolepsy as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation","volume":"31","author":"Poli","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.01.033","article-title":"Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants","volume":"50","author":"Ahmed","year":"2014","journal-title":"J Autoimmun"},{"issue":"25","key":"10.1016\/j.vaccine.2015.10.080_bib1410","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1016\/j.vaccine.2014.03.085","article-title":"The adjuvant component \u03b1-tocopherol triggers via modulation of Nrf2 the expression and turnover of hypocretin in vitro and its implication to the development of narcolepsy","volume":"32","author":"Masoudi","year":"2014","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2015.10.080_bib1415","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/dmcn.12543","article-title":"The roles of influenza virus antigens and the AS03 adjuvant in the 2009 pandemic vaccine associated with narcolepsy needs further investigation","volume":"56","author":"Johansen","year":"2014","journal-title":"Dev Med Child Neurol"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2015.10.080_bib1420","first-page":"72","article-title":"Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009\u20132010 mass vaccination campaign in France. Fundamental and Clinical Pharmacology 2011","volume":"25","author":"Durrieu","year":"2011","journal-title":"Societe Francaise de Pharmacologie et de Therapeutique"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2015.10.080_bib1425","first-page":"83","article-title":"Increased incidence of narcolepsy after the A\/H1N1 pandemic influenza vaccination campaign in the Nordic countries","volume":"21","author":"Partinen","year":"2012","journal-title":"J Sleep Res"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib1430","doi-asserted-by":"crossref","first-page":"e33536","DOI":"10.1371\/journal.pone.0033536","article-title":"AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland","volume":"7","author":"Nohynek","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1435","series-title":"Increased risk of narcolepsy observed also among adults vaccinated with Pandemrix in Finland","author":"National Institute for Health and Welfare","year":"2013"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1440","series-title":"Narcolepsy in association with pandemic influenza vaccination (a multi-county European epidemiological investigation)","author":"European Centre for Disease Prevention and Control","year":"2012"},{"issue":"8","key":"10.1016\/j.vaccine.2015.10.080_bib1445","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.vaccine.2012.12.015","article-title":"The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns","volume":"31","author":"Wijnans","year":"2013","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.080_bib1450","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3109\/00365548.2011.580777","article-title":"Explorations of clinical trials and pharmacovigilance databases of MF59\u00ae-adjuvanted influenza vaccines for associated cases of narcolepsy","volume":"43","author":"Tsai","year":"2011","journal-title":"Scand J Infect Dis"},{"issue":"50","key":"10.1016\/j.vaccine.2015.10.080_bib1455","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1016\/j.vaccine.2013.10.031","article-title":"Evaluating the safety of influenza vaccine using a claims-based health system","volume":"31","author":"McCarthy","year":"2013","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2015.10.080_bib1460","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1212\/WNL.0000000000000987","article-title":"Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States","volume":"83","author":"Duffy","year":"2014","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.vaccine.2015.10.080_bib1465","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1440-1843.2012.02178.x","article-title":"Sleepiness that cannot be overcome: narcolepsy and cataplexy","volume":"17","author":"Han","year":"2012","journal-title":"Respirology"},{"issue":"8","key":"10.1016\/j.vaccine.2015.10.080_bib1470","doi-asserted-by":"crossref","first-page":"e68402","DOI":"10.1371\/journal.pone.0068402","article-title":"No serological evidence of influenza A H1N1pdm09 virus infection as a contributing factor in childhood narcolepsy after Pandemrix vaccination campaign in Finland","volume":"8","author":"Mel\u00e9n","year":"2013","journal-title":"PLOS ONE"},{"issue":"12","key":"10.1016\/j.vaccine.2015.10.080_bib1475","doi-asserted-by":"crossref","first-page":"e114361","DOI":"10.1371\/journal.pone.0114361","article-title":"Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk","volume":"9","author":"Vaarala","year":"2014","journal-title":"PLOS ONE"},{"issue":"216","key":"10.1016\/j.vaccine.2015.10.080_bib1480","doi-asserted-by":"crossref","first-page":"216ra176","DOI":"10.1126\/scitranslmed.3007762","article-title":"CD4+ T cell autoimmunity to hypocretin\/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy","volume":"5","author":"De la Herr\u00e1n-Arita","year":"2013","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib1485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vaccine.2007.10.043","article-title":"All that palsies is not Bell's \u2013 the need to define Bell's palsy as an adverse event following immunization","volume":"26","author":"Rath","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1490","series-title":"Harrison's principles of internal medicine","article-title":"Chapter 376. Trigeminal neuralgia, Bell's Palsy, and other cranial nerve disorders","author":"Beal","year":"2012"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.080_bib1495","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1056\/NEJMp048006","article-title":"Escherichia coli enterotoxin, and Bell's palsy","volume":"350","author":"Couch","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.080_bib1500","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.080_bib1505","doi-asserted-by":"crossref","first-page":"e6999","DOI":"10.1371\/journal.pone.0006999","article-title":"Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin","volume":"4","author":"Lewis","year":"2009","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib1510","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1083\/jcb.82.3.798","article-title":"Selective retrograde transsynaptic transfer of a protein, tetanus toxin, subsequent to its retrograde axonal transport","volume":"82","author":"Schwab","year":"1979","journal-title":"J Cell Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib1515","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1586\/14760584.2.2.295","article-title":"Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine","volume":"2","author":"Zurbriggen","year":"2003","journal-title":"Expert Rev Vaccines"},{"issue":"15","key":"10.1016\/j.vaccine.2015.10.080_bib1520","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1016\/j.vaccine.2006.10.006","article-title":"Bell's palsy associated with influenza vaccination: two case reports","volume":"25","author":"Chou","year":"2007","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib1525","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1590\/0004-282X20140064","article-title":"Neurological complications after H1N1 influenza vaccination: magnetic resonance imaging findings","volume":"72","author":"Lessa","year":"2014","journal-title":"Arq Neuropsiquiatr"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib1530","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/aje\/kwp345","article-title":"Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project","volume":"171","author":"Greene","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"11","key":"10.1016\/j.vaccine.2015.10.080_bib1535","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/aje\/kws197","article-title":"Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009\u20132010","volume":"175","author":"Yih","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib1540","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.pcl.2013.08.009","article-title":"Diagnosis and management of autoimmune cytopenias in childhood","volume":"60","author":"Teachey","year":"2013","journal-title":"Pediatr Clin North Am"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.080_bib1545","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2008-03-138487","article-title":"Participants. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura","volume":"112","author":"Neunert","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib1550","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.hoc.2009.08.008","article-title":"Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production","volume":"23","author":"McMillan","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib1555","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1097\/MPH.0b013e3181e33fe0","article-title":"A case of immune thrombocytopenic purpura after influenza vaccination: consequence or coincidence?","volume":"32","author":"Mantadakis","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib1560","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJM196608182750703","article-title":"Effect of live measles vaccine on the platelet count","volume":"275","author":"Oski","year":"1966","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib1565","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1542\/peds.2011-1111","article-title":"The risk of immune thrombocytopenic purpura after vaccination in children and adolescents","volume":"129","author":"O\u2019Leary","year":"2012","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib1570","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/jama.1981.03310290037020","article-title":"Vaccination-associated relapse of immune thrombocytopenia","volume":"245","author":"Kelton","year":"1981","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1575","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s10156-004-0343-1","article-title":"Relapse of idiopathic thrombocytopenic purpura caused by influenza A virus infection: a case report","volume":"10","author":"Kaneko","year":"2004","journal-title":"J Infect Chemother"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib1580","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1053\/j.ajkd.2006.04.090","article-title":"Recurrent idiopathic thrombotic thrombocytopenic purpura: a role for vaccination in disease relapse?","volume":"48","author":"Brodin-Sartorius","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"25","key":"10.1016\/j.vaccine.2015.10.080_bib1585","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1182\/blood-2012-05-431098","article-title":"A case\u2013control study to assess the risk of immune thrombocytopenia associated with vaccines","volume":"120","author":"Grimaldi-Bensouda","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib1590","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/aje\/kwt078","article-title":"Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy","volume":"178","author":"Villa","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1595","first-page":"361","article-title":"Safety of the 2010\u20132011 influenza vaccinations in the Department of Veteran Affairs, Abstracts of the 28th ICPE 2012","author":"Hur","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1600","series-title":"Vaccine","first-page":"294","article-title":"Chapter 18: influenza vaccine-live","author":"Luke","year":"2012"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib1605","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/infdis\/168.4.881","article-title":"Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia","volume":"168","author":"Rudenko","year":"1993","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.080_bib1610","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/01.inf.0000237797.14283.cf","article-title":"Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma","volume":"25","author":"Fleming","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.080_bib1615","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1097\/01.inf.0000237829.66310.85","article-title":"Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections","volume":"25","author":"Ashkenazi","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1620","article-title":"Advisory Committee on Immunization Practices (ACIP) recommends a preference for using the nasal spray flu vaccine","volume":"25","author":"CDC","year":"2014","journal-title":"Media Statement. June"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1625","series-title":"The Green Book \u2013 Influenza (Chapter 19 v8_0)","author":"Public Health England","year":"2014"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1630","volume":"vol. 39","author":"National Advisory Committee on Immunization (NACI)","year":"2013"},{"issue":"38","key":"10.1016\/j.vaccine.2015.10.080_bib1635","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1016\/j.vaccine.2008.07.013","article-title":"Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5\u201349 years of age","volume":"26","author":"Block","year":"2008","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib1640","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/01.inf.0000220229.51531.47","article-title":"A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine","volume":"25","author":"Vesikari","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"26","key":"10.1016\/j.vaccine.2015.10.080_bib1645","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1016\/j.vaccine.2011.04.022","article-title":"Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6\u201359 months of age","volume":"29","author":"Mallory","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib1650","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1542\/peds.110.4.662","article-title":"Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children","volume":"110","author":"Piedra","year":"2002","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib1655","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/infdis\/169.1.68","article-title":"A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease","volume":"169","author":"Edwards","year":"1994","journal-title":"J Infect Dis"},{"issue":"20","key":"10.1016\/j.vaccine.2015.10.080_bib1660","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199805143382002","article-title":"The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children","volume":"338","author":"Belshe","year":"1998","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib1665","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/infdis\/169.5.1121","article-title":"Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children","volume":"169","author":"Swierkosz","year":"1994","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib1670","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1750-2659.2011.00243.x","article-title":"An integrated, multi-study analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2\u201317 years","volume":"5","author":"Ambrose","year":"2011","journal-title":"Influenza Other Respir Viruses"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib1675","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/INF.0b013e31819219b8","article-title":"Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children","volume":"28","author":"Bracco Neto","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib1680","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jaci.2004.04.006","article-title":"Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing","volume":"114","author":"Heymann","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1685","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3389\/fmicb.2013.00391","article-title":"Epidemiology of virus-induced wheezing\/asthma in children","volume":"4","author":"Inoue","year":"2013","journal-title":"Front Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib1690","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1542\/peds.2006-3283","article-title":"Cytokine profiles in the respiratory tract during primary infection with human metapneumovirus, respiratory syncytial virus, or influenza virus in infants","volume":"120","author":"Melendi","year":"2007","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib1695","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1034\/j.1399-3038.2002.01093.x","article-title":"Relationships among specific viral pathogens, virus-induced interleukin-8, and respiratory symptoms in infancy","volume":"13","author":"Gern","year":"2002","journal-title":"Pediatr Allergy Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib1700","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00431-014-2277-7","article-title":"Clinical and epidemiologic factors related to subsequent wheezing after virus-induced lower respiratory tract infections in hospitalized pediatric patients younger than 3 years","volume":"173","author":"Takeyama","year":"2014","journal-title":"Eur J Pediatr"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.080_bib1705","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.tim.2014.06.002","article-title":"Ion flux in the lung: virus-induced inflammasome activation","volume":"22","author":"Triantafilou","year":"2014","journal-title":"Trends Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib1710","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/01.inf.0000109392.96411.4f","article-title":"Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents","volume":"23","author":"Bergen","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"40","key":"10.1016\/j.vaccine.2015.10.080_bib1715","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1016\/j.vaccine.2009.07.002","article-title":"A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children","volume":"27","author":"Breiman","year":"2009","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2015.10.080_bib1720","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1016\/j.vaccine.2011.02.071","article-title":"Atopy history and the genomics of wheezing after influenza vaccination in children 6\u201359 months of age","volume":"29","author":"Miller","year":"2011","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2015.10.080_bib1725","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.vaccine.2013.01.055","article-title":"A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24\u201359 months of age","volume":"31","author":"Toback","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1730","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1542\/peds.2004-2258","article-title":"Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial","volume":"116","author":"Piedra","year":"2005","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib1735","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00006454-200201000-00010","article-title":"Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma","volume":"21","author":"Redding","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib1740","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archpedi.158.1.65","article-title":"Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000\u20132001 influenza A(H1N1) and B epidemic in healthy children","volume":"158","author":"Gaglani","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"12","key":"10.1016\/j.vaccine.2015.10.080_bib1745","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1097\/00006454-200112000-00006","article-title":"Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children","volume":"20","author":"King","year":"2001","journal-title":"Pediatr Infect Dis J"},{"issue":"33","key":"10.1016\/j.vaccine.2015.10.080_bib1750","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1016\/j.vaccine.2008.05.054","article-title":"Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children","volume":"26","author":"Levin","year":"2008","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2015.10.080_bib1755","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1016\/j.vaccine.2011.03.097","article-title":"Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer","volume":"29","author":"Halasa","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib1760","doi-asserted-by":"crossref","first-page":"e983","DOI":"10.1542\/peds.2014-0887","article-title":"Safety of live-attenuated influenza vaccination in cystic fibrosis","volume":"134","author":"Boikos","year":"2014","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib1765","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0264-410X(93)90194-3","article-title":"Comparison of live attenuated and inactivated influenza vaccines in schoolchildren in Russia: I. Safety and efficacy in two Moscow schools, 1987\/88","volume":"11","author":"Slepushkin","year":"1993","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib1770","first-page":"77","article-title":"Clinical and epidemiological evaluation of a live, cold-adapted influenza vaccine for 3\u201314-year-olds","volume":"74","author":"Rudenko","year":"1996","journal-title":"Bull World Health Organ"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib1775","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4161\/hv.22317","article-title":"A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac) in India","volume":"9","author":"Kulkarni","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1780","article-title":"Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized clinical trial among children in urban Bangladesh","author":"Ortiz","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1785","article-title":"A randomized, double-blind, placebo-controlled trial on the clinical safety and efficacy of a single dose of trivalent seasonal live-attenuated influenza vaccine among children aged 24 through 59 months in Bangladesh","author":"Brooks","year":"2015","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib1790","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/infdis\/152.6.1212","article-title":"Use of influenza A virus vaccines in seronegative children: live cold-adapted versus inactivated whole-virus","volume":"152","author":"Feldman","year":"1985","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib1795","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1542\/peds.2010-2777","article-title":"Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months","volume":"128","author":"Skowronski","year":"2011","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.080_bib1800","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/INF.0b013e31824e2924","article-title":"A randomized, controlled trial in children to assess the immunogenicity and safety of a thimerosal-free trivalent seasonal influenza vaccine","volume":"31","author":"Domachowske","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1805","doi-asserted-by":"crossref","first-page":"d3908","DOI":"10.1136\/bmj.d3908","article-title":"Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case\u2013control study in Europe","volume":"343","author":"Dieleman","year":"2011","journal-title":"BMJ"},{"issue":"14","key":"10.1016\/j.vaccine.2015.10.080_bib1810","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1212\/WNL.0b013e31828ab26f","article-title":"Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination","volume":"80","author":"Szak\u00e1cs","year":"2013","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.vaccine.2015.10.080_bib1815","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2807\/1560-7917.ES2014.19.17.20789","article-title":"Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009\u2013December 2010","volume":"19","author":"O\u2019Flanagan","year":"2014","journal-title":"Euro Surveill"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.080_bib1820","doi-asserted-by":"crossref","first-page":"e108489","DOI":"10.1371\/journal.pone.0108489","article-title":"Risk of narcolepsy associated with inactivated adjuvanted (AS03) A\/H1N1 (2009) pandemic influenza vaccine in Quebec","volume":"9","author":"Montplaisir","year":"2014","journal-title":"PLOS ONE"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib1825","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.humimm.2008.05.001","article-title":"Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies","volume":"69","author":"Solberg","year":"2008","journal-title":"Hum Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib1830","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4161\/hv.7.1.13411","article-title":"Assessment of the safety, tolerability and kinetics of the immune response to A\/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age","volume":"7","author":"Arguedas","year":"2011","journal-title":"Hum Vaccin"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib1835","first-page":"292","article-title":"Preventing pandemic influenza: an update on vaccine development","volume":"24","author":"Atmar","year":"2007","journal-title":"Infect Med"},{"issue":"234","key":"10.1016\/j.vaccine.2015.10.080_bib1840","doi-asserted-by":"crossref","first-page":"234ra55","DOI":"10.1126\/scitranslmed.3008761","article-title":"A cell culture-derived MF59-adjuvanted pandemic A\/H7N9 vaccine is immunogenic in adults","volume":"6","author":"Bart","year":"2014","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.vaccine.2015.10.080_bib1845","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.4161\/hv.24832","article-title":"Immunogenicity and safety of three 2010\u20132011 seasonal trivalent influenza vaccines in Chinese toddlers, children and older adults: a double-blind and randomized trial","volume":"9","author":"Luo","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib1850","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00006454-200404000-00005","article-title":"Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children","volume":"23","author":"Kanra","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib1855","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/INF.0b013e3182068f33","article-title":"Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children","volume":"30","author":"Scheifele","year":"2011","journal-title":"Pediatr Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.080_bib1860","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3855\/jidc.4594","article-title":"Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children","volume":"8","author":"Solares","year":"2014","journal-title":"J Infect Dev Ctries"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib1865","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1750-2659.2012.00364.x","article-title":"Increased reactions to pediatric influenza vaccination following concomitant pneumococcal vaccination","volume":"7","author":"Van Buynder","year":"2012","journal-title":"Influenza Other Respir Viruses"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib1870","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.3928\/01477447-20120123-26","article-title":"Progressive osteolysis and surface chondrolysis of the proximal humerus following influenza vaccination","volume":"35","author":"Messerschmitt","year":"2012","journal-title":"Orthopedics"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1875","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/B978-0-444-52001-2.00008-X","article-title":"The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment","volume":"122","author":"Robinson","year":"2014","journal-title":"Handb Clin Neurol"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.080_bib1880","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.080_bib1885","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1442-200X.2011.03501.x","article-title":"Acute disseminated encephalomyelitis following 2009 H1N1 influenza vaccine","volume":"54","author":"Fujii","year":"2012","journal-title":"Pediatr Int"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib1890","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2013.10.003","article-title":"The spectrum of post-vaccination inflammatory CNS demyelinating syndromes","volume":"13","author":"Karussis","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"23","key":"10.1016\/j.vaccine.2015.10.080_bib1895","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1212\/WNL.0b013e31821e552a","article-title":"Common viruses associated with lower pediatric multiple sclerosis risk","volume":"76","author":"Waubant","year":"2011","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib1900","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/1352458512469693","article-title":"Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis","volume":"19","author":"Waubant","year":"2013","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.080_bib1905","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/1352458511417253","article-title":"H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study","volume":"18","author":"Farez","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1910","series-title":"Occurrence of narcolepsy with cataplexy among children and adolescents in relation to the H1N1 pandemic and Pandemrix vaccinations: results of a case inventory study by the MPA in Sweden during 2009\u20132010","author":"Medical Products Agency (Lakemedelsverket)","year":"2011"},{"issue":"Pt 8","key":"10.1016\/j.vaccine.2015.10.080_bib1915","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1093\/brain\/awt187","article-title":"Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France","volume":"136","author":"Dauvilliers","year":"2013","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.080_bib1920","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/014107689709000916","article-title":"What caused the 1918\u201330 epidemic of encephalitis lethargica?","volume":"90","author":"Dourmashkin","year":"1997","journal-title":"J R Soc Med"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.080_bib1930","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1086\/386330","article-title":"Intranasal influenza vaccine in a working population","volume":"38","author":"Sendi","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2015.10.080_bib1935","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/pds.998","article-title":"A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS) \u2013 United States, 1991\u20132001","volume":"13","author":"Zhou","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib1940","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4161\/hv.2790","article-title":"Bell's palsy and parenteral inactivated influenza vaccine","volume":"2","author":"Stowe","year":"2006","journal-title":"Hum Vaccin"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.080_bib1945","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3345\/kjp.2011.54.10.422","article-title":"An adverse event following 2009 H1N1 influenza vaccination: a case of acute disseminated encephalomyelitis","volume":"54","author":"Lee","year":"2011","journal-title":"Korean J Pediatr"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.080_bib1950","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2125.2003.01790.x","article-title":"MMR vaccine and idiopathic thrombocytopaenic purpura","volume":"55","author":"Black","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.080_bib1955","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/adc.84.3.227","article-title":"Idiopathic thrombocytopenic purpura and MMR vaccine","volume":"84","author":"Miller","year":"2001","journal-title":"Arch Dis Child"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.080_bib1960","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/j.vaccine.2006.10.054","article-title":"Vaccination associated thrombocytopenic purpura in children","volume":"25","author":"Rajantie","year":"2007","journal-title":"Vaccine"},{"issue":"S1","key":"10.1016\/j.vaccine.2015.10.080_bib1965","first-page":"1","article-title":"Idiopathic thrombocytopenic purpura after seasonal influenza vaccination","volume":"23","author":"Liu","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.080_bib1970","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/infdis\/163.5.1023","article-title":"The A\/Mallard\/6750\/78 avian-human, but not the A\/Ann Arbor\/6\/60 cold-adapted, influenza A\/Kawasaki\/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children","volume":"163","author":"Steinhoff","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.080_bib1975","series-title":"Presentation at ACIP Influenza Working Group Meeting","article-title":"Interim influenza vaccine safety update: live attenuated influenza vaccine and inactivated influenza vaccine in persons <18 years of age, US, 2013\u201314","author":"Cano","year":"2014"},{"issue":"July (294)","key":"10.1016\/j.vaccine.2015.10.080_bib2975","doi-asserted-by":"crossref","first-page":"294ra105","DOI":"10.1126\/scitranslmed.aab2354","article-title":"Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2","volume":"7","author":"Ahmed","year":"2015","journal-title":"Sci Transl Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15015236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15015236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T11:10:11Z","timestamp":1654254611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15015236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":395,"alternative-id":["S0264410X15015236"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.080","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}